The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain

Molecular and Cellular Biology

Volumn 31, Issue 16, 2011, Pages 3497-3510

  Burgermeister, Elke ^a   Friedrich, Teresa ^b   Hitkova, Ivana ^b   Regel, Ivonne ^b   Einwächter, Henrik ^b   Zimmermann, Wolfgang ^c   Röcken, Christoph ^d   Perren, Aurel ^e   Wright, Matthew B ^f   Schmid, Roland M ^b   Seger, Rony ^g   Ebert, Matthias P A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; DOCKING PROTEIN; DOCKING PROTEIN 1; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAS PROTEIN; ROSIGLITAZONE; SCAFFOLD PROTEIN; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSOL; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSLOCATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; STOMACH; STOMACH CANCER; STOMACH EPITHELIUM; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BINDING SITES; CAVEOLIN 1; CELL PROLIFERATION; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; MICE; PHOSPHOPROTEINS; PPAR GAMMA; RAS PROTEINS; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

MURINAE;

EID: 79961145162     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01421-10     Document Type: Article

References (68)

1. Agostini, M., et al. 2004. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology 145:1527-1538.
2. Barresi, V., G. Giuffre, E. Vitarelli, P. Todaro, and G. Tuccari. 2008. Caveolin-1 immuno-expression in human gastric cancer: histopathogenetic hypotheses. Virchows Arch. 453:571-578.
3. Berger, A. H., et al. 2010. Identification of DOK genes as lung tumor suppressors. Nat. Genet. 42:216-223.
4. Burgermeister, E., et al. 2007. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol. Cell. Biol. 27:803-817.
5. Burgermeister, E., et al. 2006. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. 20:809-830.
6. Burgermeister, E., and R. Seger. 2007. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 6:1539-1548.
7. Burgermeister, E., and R. Seger. 2008. PPARgamma and MEK Interactions in Cancer. PPAR Res. 2008:309469.
8. Burgermeister, E., L. Tencer, and M. Liscovitch. 2003. Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 22:3888-3900.
9. Burgermeister, E., et al. 2007. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res. 67:8519-8526.
10. Chen, X., et al. 2010. Integrin alpha1beta1 regulates epidermal growth factor receptor activation by controlling peroxisome proliferator-activated receptor gamma-dependent caveolin-1 expression. Mol. Cell. Biol. 30:3048-3058.
11. Choi, J. H., et al. 2010. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466:451-456.
12. Chuderland, D., A. Konson, and R. Seger. 2008. Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol. Cell 31:850-861.
13. Couet, J., S. Li, T. Okamoto, T. Ikezu, and M. P. Lisanti. 1997. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272:6525-6533.
14. Couet, J., M. Sargiacomo, and M. P. Lisanti. 1997. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J. Biol. Chem. 272: 30429-30438.
15. Demers, A., et al. 2009. A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages. PLoS One 4:e7728.
16. Ebert, M. P., et al. 2006. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J. Proteome Res. 5:2152-2158.
17. Gampe, R. T., Jr., et al. 2000. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 5:545-555.
18. Gratton, J. P., et al. 2003. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4:31-39.
19. Gupta, R. A., et al. 2001. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J. Biol. Chem. 276: 31059-31066.
20. Han, S., N. Sidell, P. B. Fisher, and J. Roman. 2004. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin. Cancer Res. 10:1911-1919.
21. He, Q., J. Chen, H. L. Lin, P. J. Hu, and M. H. Chen. 2007. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases. Chin. Med. J. (Engl.). 120:1498-1504.
22. Hegele, R. A., H. Cao, C. Frankowski, S. T. Mathews, and T. Leff. 2002. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51:3586-3590.
23. Holt, J. A., et al. 2003. Helix 1/8 interactions influence the activity of nuclear receptor ligand-binding domains. Mol. Endocrinol. 17:1704-1714.
24. Hosooka, T., et al. 2008. Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat. Med. 14:188-193.
25. Hubert, P., V. Ferreira, P. Debre, and G. Bismuth. 2000. Molecular cloning of a truncated p62Dok1 isoform, p22Dok(del). Eur. J. Immunogenet. 27: 145-148.
26. Karapetis, C. S., et al. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359:1757-1765.
27. Kawai, M., et al. 2010. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc. Natl. Acad. Sci. U. S. A. 107:10508-10513.
28. Kelly, D., et al. 2004. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat. Immunol. 5:104-112.
29. Kobayashi, R., R. Patenia, S. Ashizawa, and J. Vykoukal. 2009. Targeted mass spectrometric analysis of N-terminally truncated isoforms generated via alternative translation initiation. FEBS Lett. 583:2441-2445.
30. Lefebvre, A. M., et al. 1998. Activation of the peroxisome proliferatoractivated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4:1053-1057.
31. Lehrke, M., and M. A. Lazar. 2005. The many faces of PPARgamma. Cell 123:993-999.
32. Leung, W. K., et al. 2004. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 53:331-338.
33. Li, J., et al. 2005. Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation. Cell Cycle 4:1817-1825.
34. Liu, J., H. Wang, Y. Zuo, and S. R. Farmer. 2006. Functional interaction between peroxisome proliferator-activated receptor gamma and betacatenin. Mol. Cell. Biol. 26:5827-5837.
35. Llaverias, G., et al. 2004. Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J. Lipid Res. 45:2015-2024.
36. Lu, J., et al. 2005. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res. 65: 4769-4774.
37. Mashima, R., Y. Hishida, T. Tezuka, and Y. Yamanashi. 2009. The roles of Dok family adapters in immunoreceptor signaling. Immunol. Rev. 232:273-285.
38. Matthews, L., et al. 2008. Caveolin mediates rapid glucocorticoid effects and couples glucocorticoid action to the antiproliferative program. Mol. Endocrinol. 22:1320-1330.
39. McAlpine, C. A., Y. Barak, I. Matise, and R. T. Cormier. 2006. Intestinalspecific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int. J. Cancer 119:2339-2346.
40. McCoy, M. S., C. I. Bargmann, and R. A. Weinberg. 1984. Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-oncogene. Mol. Cell. Biol. 4:1577-1582.
41. Meza-Junco, J., H. J. Au, and M. B. Sawyer. 2009. Trastuzumab for gastric cancer. Expert Opin. Biol. Ther. 9:1543-1551.
42. Nakajima, A., et al. 2001. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120: 460-469.
43. Niu, Y., et al. 2006. A nuclear export signal and phosphorylation regulate Dok1 subcellular localization and functions. Mol. Cell. Biol. 26:4288-4301.
44. Nolte, R. T., et al. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143.
45. Nomura, S., et al. 2006. Differential expression of peroxisome proliferatoractivated receptor in histologically different human gastric cancer tissues. J. Exp. Clin. Cancer Res. 25:443-448.
46. Parton, R. G., and K. Simons. 2007. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 8:185-194.
47. Pascual, G., et al. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437: 759-763.
48. Rajab, A., et al. 2010. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 6:e1000874.
49. Razani, B., et al. 2002. Caveolin-1-deficient mice are lean, resistant to dietinduced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol. Chem. 277:8635-8647.
50. Razani, B., et al. 2001. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276:38121-38138.
51. Rim, J. S., B. Xue, B. Gawronska-Kozak, and L. P. Kozak. 2004. Sequestration of thermogenic transcription factors in the cytoplasm during development of brown adipose tissue. J. Biol. Chem. 279:25916-25926.
52. Rumi, M. A., et al. 2004. Peroxisome proliferator-activated receptor gammadependent and -independent growth inhibition of gastrointestinal tumour cells. Genes Cells 9:1113-1123.
53. Sato, H., et al. 2000. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br. J. Cancer 83:1394-1400.
54. Schlegel, A., C. Wang, B. S. Katzenellenbogen, R. G. Pestell, and M. P. Lisanti. 1999. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J. Biol. Chem. 274:33551-33556.
55. Sharma, C., A. Pradeep, R. G. Pestell, and B. Rana. 2004. Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes. J. Biol. Chem. 279: 16927-16938.
56. Shimada, T., et al. 2007. Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates trefoil factor family 2 (TFF2) expression in gastric epithelial cells. Int. J. Biochem. Cell Biol. 39:626-637.
57. Simha, V., and A. Garg. 2009. Inherited lipodystrophies and hypertriglyceridemia. Curr. Opin. Lipidol. 20:300-308.
58. Stremmel, W., L. Pohl, A. Ring, and T. Herrmann. 2001. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 36:981-989.
59. Thompson, J., et al. 2000. A transgenic mouse line that develops early-onset invasive gastric carcinoma provides a model for carcinoembryonic antigentargeted tumor therapy. Int. J. Cancer 86:863-869.
60. van Beekum, O., V. Fleskens, and E. Kalkhoven. 2009. Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. Obesity (Silver Spring) 17:213-219.
61. von Knethen, A., et al. 2007. PPARgamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. J. Cell Biol. 176:681-694.
62. von Knethen, A., N. Tzieply, C. Jennewein, and B. Brune. 2010. Caseinkinase-II-dependent phosphorylation of PPARgamma provokes CRM1-mediated shuttling of PPARgamma from the nucleus to the cytosol. J. Cell Sci. 123:192-201.
63. Wainberg, Z. A., et al. 2010. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 16: 1509-1519.
64. Wang, H., L. Qiang, and S. R. Farmer. 2008. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 28:188-200.
65. Wei, S., et al. 2008. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J. Biol. Chem. 283:26759-26770.
66. Xing, X., et al. 2009. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. Hepatology 49:979-988.
67. Xu, W., et al. 2010. PPARgamma polymorphisms and cancer risk: a metaanalysis involving 32,138 subjects. Oncol. Rep. 24:579-585.
68. Yuasa, Y. 2003. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat. Rev. Cancer 3:592-600.